Meta-analysis The Lancet Oncology on immunotherapy for #EGFR NSCLC post TKIs (32 trials, 2886 pts). IO monotherapy had shorter PFS than chemo (HR 1.73) but chemo-IO (HR 0.77) and chemo-IO with antiangiogenic therapy yielded best PFS (HR 0.54). thelancet.com/journals/lanon…

🔥#WCLC24 abstracts 🧬New Horizons in Targeting KRAS G12C ✅Chairs: Drs. Lyudmila Bazhenova & Junko Tanizaki 🎙️Dr. Yutaka Fujiwara 🎯Olomorasib with Pembrolizumab + Chemo as 1st-Line Treatment in Pts with KRAS G12C-m Advanced NSCLC #LCSM IASLC OncoAlert cattendee.abstractsonline.com/meeting/20598

#lcsm #egfr Balazs Halmos Stephen V Liu, MD Biagio Ricciuti, MD PhD Bruna Pellini, MD Eric K. Singhi, MD How manage this challenge case based in #liquidbiopsy EGFR Resisters Dana Farber's EGFR-Mutant Lung Cancer Center gilberto lopes

Financial toxicity matters! Check this article out from JCO Oncology Practice and follow us for more OncoAlert

NEJM Dr. Glaucomflecken Oh you better have gotten us open access to those articles, sir Dr. Glaucomflecken, cause you this:

Os artistas desistiram de “salvar” a Amazônia. gazetadopovo.com.br/vozes/nikolas-…

Below is a list of "Never Words" to avoid around patients. 🧐 doi.org/10.1016/j.mayo…

This is a very very important point to keep in mind OncoAlert JAMA Oncology JCO Global Oncology

Nice and provocative real-world data of ADCs sequencing. Congrats to the authors! 🧐ADC cross-resistance - which may imply TOPO1 resistance as a major resistance mechanism. 🧐Disappointing PFS2 regardless of sequence 🧐No role for intermediate ttx line OncoAlert #bcsm

📰 New research in Cell shows the key role of tumor-associated B cells in breast cancer & other cancers #HER2DX & #TNBCDX are the only gene assays using B-cell components to predict outcomes in breast cancer #COI Read more: cell.com/cell/fulltext/…

Count down to #ESMO2024 ESMO - Eur. Oncology with the great OncoAlert 🥁

Grok “Generate an image as if Voldemort and a Sith Lord had a baby and he became a judge in Brazil” It’s uncanny! 🤣🤣

📌 Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights OncoAlert #OncoAlertAF ascopubs.org/doi/10.1200/OP…

Can’t miss updates from #ESMO24 OncoAlert

Together is better OncoAlert ESMO - Eur. Oncology

Neoadjuvant Immunotherapy—From Trials to Practice out on JAMA Oncology by Dr. E Mittendorf and our @oncoAlert #BreastCancer Faculty Sara Tolaney of Dana-Farber 🇺🇸 Immunotherapy, particularly immune checkpoint♟️ inhibition, has become a key🔑component of #cancer treatment, with approvals

IRRETOCÁVEL! Marco Aurélio afirma que banir pessoas das redes sociais implica em retrocessos, que inverdades devem ser combatidas com verdades e não com censura de ideias.

Dear friends, I don't know if you all know, but it's likely that X will be banned from the country and I will have limited access. I'm leaving my email and Instagram profile so we can continue interacting and I hope this situation has a quick solution. instagram.com/drjosefernando…

Muito bom fazer parte desse time empolgado com a disseminação de conhecimento pelo mundo 🌎 OncoAlert Gil Morgan, MD #OncoAlertAF

Impactful #survonc study in Journal of Cancer Survivorship #Cancerrehab after #bcsm varies by patient. ⬆️ use: young🤱 educated 👩‍🎓White 👩‍🌾rural survivors. Need more focus for #PoC ⬇️#SES 👵#GeriOnc Bravo Jessica Gorzelitz, PhD, MS Nicole L. Stout DPT, FAPTA Rachelle Brick, PhD, MSPH, OTR/L link.springer.com/article/10.100… OncoAlert🚨